Playback speed
10 seconds
ESMO 2023 Insights: "RAMOSE Trial - Osimertinib+/-Ramucirumab in TKI-Naïve EGFRm mNSCLC"
By
Insights from 2023 ESMO Annual Meeting
FEATURING
Xiuning Le
By
Insights from 2023 ESMO Annual Meeting
FEATURING
Xiuning Le
213 views
November 8, 2023
Login to view comments.
Click here to Login